Recombinant Human Growth Hormone (HGH) CAS: 12629-01-5
Biochemical Materials 2025-03-18
Key Properties
| Attribute | Details |
|---|---|
| CAS Number | 12629-01-5 |
| Production Method | Recombinant DNA technology (E. coli/mammalian cells) |
| Molecular Weight | ~22 kDa |
| Amino Acid Chain | 191 residues (matches endogenous HGH) |
| Primary Function | Stimulates cell growth, metabolism, and tissue repair |
Therapeutic Applications
| Approved Uses | Off-Label/Research |
|---|---|
| Pediatric GHD | Muscle wasting in AIDS/cachexia |
| Adult GHD | Anti-aging (limited evidence, controversial) |
| Turner syndrome | |
| Chronic kidney disease |
Administration & Safety
| Route | Subcutaneous injection |
|---|---|
| Side Effects | Joint pain, edema, hypoglycemia |
| Contraindications | Active cancer, intracranial hypertension |
| Storage | 2–8°C (avoid freezing) |
Regulatory Status
| Agency | Status |
|---|---|
| FDA/EMA | Approved for deficiency-related conditions |
| Off-label use debated due to risks |
